Tokyo, July 19, 2006 (JCN) - Trans Genic, a biotech company specializing in genome function research, and the Kumamoto Techno Industrial foundation have concluded an exclusive license agreement on anti-HIV antibodies PCT/JP2004/003046.
The partners have produced a monoclonal antibody with a high level of neutralization activity against HIV as part of a therapeutic drug for AIDS.
The findings were based on experiments on genetically modified mice with high affinity antibody-producing cells.
The Kumamoto foundation has filed an application for international patent for the monoclonal antibody.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
 |
|
Trans Genic and Kumamoto Foundation Conclude Anti-HIV Antibody License Agreement
(July 19, 2006)
|
|
|
Trans Genic and Kumamoto Foundation Conclude Anti-HIV Antibody License Agreement
(July 19, 2006)
|
|
|
Trans Genic Receives Japanese Patent on Cancer Diagnosis Method Using Urine Samples
(July 4, 2006)
|
|
|
Trans Genic Receives Japanese Patent on Cancer Diagnosis Method Using Urine Samples
(July 4, 2006)
|
|
|
TRANS GENIC to Dissolve Business Partnership with livedoor Group
(Feb 20, 2006)
|
|
|
Hitachi, TransGenic to Form Business Alliance in Life Science R&D Support Service
(Oct 5, 2005)
|
|
|
Trans Genic Receives Japanese Patents on Knockout Mice for Drug Development
(Oct 4, 2005)
|
|
|
TransGenic Wins Aid for Gene Knockout Mice Research from Hyogo Prefecture
(Aug 29, 2005)
|
|
|
Ecogenomics Releases Innovative DNA Microarrays for Biological Assessment of Chemical Substances
(Aug 26, 2005)
|
|
|
Trans Genic, Vital Star Conclude Joint Research Agreement for Knockout Mice
(May 30, 2005)
|
|
|
